Introduction
Why should one ask about the possible aim and role for neoadjuvant hormonal therapy prior to radical prostatectomy or radiation therapy in prostate? First, there are a number of bene®ts that neoadjuvant hormone deprivation might be expected to offer. For example, reducing the size of the prostate with hormonal deprivation would be very bene®cial, as would downstaging of the cancer, to obtain a better prognosis. In addition, if it could also help reduce the incidence of extraprostatic disease and positive margins, this would be a signi®cant advantage. Other potential effects include reducing the morbidity associated with local treatments and improving overall survival. Numerous studies have been carried out to investigate all these potential bene®ts.
Which subsets of patients are likely candidates for neoadjuvant hormonal therapy? Clearly, since neoadjuvant therapy is intended only for local therapy, it is unsuitable for patients with metastatic disease. In addition, it is not suitable for treating very small tumours that are known to be con®ned within the prostate and can be successfully managed with surgery or radiotherapy. Therefore, neoadjuvant hormonal therapy appears to be best suited to T2 ± 4 tumors, particularly pT3 which is no longer clinically localized. This is supported by the wellrecognized fact that there is a high incidence of clinical understaging in prostate cancer, with clinical T2 tumors found in many cases to be pT3 or greater on pathologic examination. In this regard, neoadjuvant hormonal therapy may be useful for reducing the percentage of pT3 disease, as well as increasing the percentage of organ-con®ned T2 disease when a cT3 cancer is suspected (Table 1) .
Neoadjuvant hormonal therapy in conjunction with radical prostatectomy: the French experience
In conjunction with surgery, we have participated in a multicenter French study comparing maximal androgen blockade (MAB) prior to radical prostatectomy with radical prostatectomy alone (direct surgery, DS). In this study, ultrasound was used to determine prostate size and check if there was indeed a downsizing following preoperative androgen deprivation. Furthermore, surgeons were asked if downsizing, if any, made the surgical procedure any easier. 1,2
Pathological and clinical criteria
Pathological criteria included factors such as the effect of androgen deprivation on downstaging as well as on margin-positivity status. Clinical criteria included the effect of neoadjuvant androgen deprivation on continence, urinary symptoms and impotence. Our results showed that there is about a 35% reduction in the size of the prostate.
Dif®culty in surgery
The second issue addressed was whether reduction of prostate size would contribute to making surgery any easier. In this regard, surgeons were asked to assess the dif®culty in dissection of the prostate on a scale of 1 ± 3. Preoperative androgen deprivation was shown to make the surgical procedure not signi®cantly more dif®cult in the MAB group compared to the DS group, with the only difference reported being that dissection of seminal vesicles were more dif®cult to perform in the MAB group. One possible explanation for this may be that there were more T3 patients in the MAB group than in the DS group.
Pathological investigations
Pathological investigations were carried out using a scoring system from 7 2 to 1 in which downstaging was scored as follows: from cT3 to cT1 ( 7 2), from cT2 to cT1 ( 7 1), and no downstaging (0). Conversely, upstaging from any cT by one stage (e.g. cT2 to cT3) received a score of 1. As a result, it was clearly shown that in the MAB group the staging remained unchanged in 59% of patients, while 40% showed downstaging by one stage, and 1% by two stages. The highest percentage of improvement comprised those with an initial staging of cT3, although this subset accounted for only 11 patients.
With regard to the Gleason score, there was no difference between the two groups, and no downgrading was seen in these groups. However, the histopathological characteristics of the prostate were found to change after maximal androgen blockade, thus making it more dif®cult to evaluate the Gleason score. Thus, in pathological terms, the Gleason score may not have the same meaning following androgen blockade.
In contrast, margin positivity status was shown to be signi®cantly improved in the MAB group at 31% vs 54% in the DS group. Urinary symptom scores at inclusion and before and after surgery were assessed to see if neoadjuvant androgen deprivation would give better results than surgery alone. This showed that the difference seen between the two groups was due to the downsizing of the prostate associated with hormonal deprivation, although this difference disappeared after surgery.
Potency and continence: QOL issues
Potency and continence were shown to be obviously very important factors affecting the patient's quality of life. At inclusion, about 80% of patients were able to achieve an erection; however, 77% had become impotent before surgery due to the effects of maximum androgen blockade. After surgery, only 2% in each group were able to achieve an erection, and although this ®gure improved after 1 year, only about 10% in both groups were capable of erections, showing that neoadjuvant therapy had no bene®cial or harmful effect on this parameter.
Patients were also assessed for continence status in terms of their need to wear incontinence pads after radical prostatectomy. Although there was signi®cantly less need for pads in the MAB group at 1.5 months, this difference had disappeared at 12-month follow-up. In terms of overall results, there were no clinical ®ndings of any major difference between the two groups, with only a small difference seen at 1.5 months and 3 months with regard to continence status, which is unlikely to suggest a clear bene®t for preoperative androgen deprivation.
Review of the literature: radical prostatectomy with or without neoadjuvant hormonal therapy
In regard to the effect of pathological downstaging on prognosis, a survey of the literature shows that there were three published studies in 1997 which found no signi®-cant difference between radical prostatectomy alone and radical prostatectomy plus hormonal therapy (Table 2) , although in these studies patients were followed up for relatively long periods of 2 y or more. 3 ± 5 There has been a considerable number of studies comparing the effect of radical prostatectomy with or without androgen blockade on positive margins (Table  3) . 1,5 ± 11 All of these studies have shown an improved positive margin rate ranging between 20% and 30% in patients receiving hormone deprivation before radical prostatectomy. It is clear that prostate volume is reduced by neoadjuvant hormonal therapy before radical prostatectomy, although this has had no bene®cial effect on local control. In addition, androgen deprivation has failed to make surgery any easier or reduce blood loss during surgery.
In this regard, the key endpoint is overall survival and, at present, preoperative androgen deprivation does not appear to improve it, although this needs to be con®rmed in a large-scale study with a longer follow-up.
Review of the literature: radiation with or without neoadjuvant hormonal therapy
A second area where neoadjuvant hormonal therapy might be of use is radiation therapy (Table 4) . A study published by Pilepich et al in 1995 had a long-term followup averaging 4.5 y. 12 In this study, in which patients in the combined treatment arm received 2 months of hormone deprivation prior to radiation therapy, then a further 2 months during radiation, statistically signi®cant differences were shown in favor of combined therapy in terms of improved local control and disease-free survival, although the impact on overall survival is still unknown and longer follow-up may be required. Two other studies published in 1995 showed better local control and survival without evidence of biological progression in patients receiving androgen deprivation prior to radiation, as well as a reduction in positive biopsies after irradiation. However, again, there were no data available on overall survival.
More recently, Zelefsky et al looked at the clinical target volume consisting of the prostate and seminal vesicles in a study using conformal radiation therapy, which showed that the planned target volume was greater than the clinical target volume. 13 While this study was not designed to evaluate the effect of neoadjuvant hormonal therapy, 29% of patients had received this treatment to produce downsizing, with up to 81 Gy of radiation delivered to the bladder, rectum, seminal vesicles and prostate. This study demonstrated that 4 y survival depended on the number of favourable classical prognostic factors, including PSA, staging and Gleason score (Table 5) , while the response was found to be better if 75.6 Gy or above was used.
Conclusion
It is clear from the published data that neoadjuvant hormonal therapy administered before local treatment, whether radical prostatectomy or radiation therapy, reduces the prostate volume. Although this can lead to better local control in some cases, the impact on overall survival still remains unknown. 
